Evaluation of a new imaging technique to locate, prior to surgery, the lesions producing insulin in excess in patients with endogenous hyperinsulinar hypoglycemia.

111In-DTPA-exendine 4 PET/CT in patients with AHH – a prospective comparative evaluation of preoperative imaging - BetaCure

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2015-003317-22-FR

Enrollment

Registered

2017-02-02

Start date

2017-09-28

Completion date

Unknown

Last updated

2018-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

MedDRA version: 19.1 Level: PT Classification code 10061211 Term: Hyperinsulinism System Organ Class: 10027433 - Metabolism and nutrition disorders

Interventions

Product Name: 111In-DTPA-Exendine-4 Pharmaceutical Form: Solution for injection Trade Name: OctréoScan Product Name: 111In-DTPA-octreotide Pharmaceutical Form: Lyophilisate and solvent for solution f

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 28 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 28

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Main Objective: ;Secondary Objective: ;Primary end point(s):	—

Countries

France

Contacts

Public ContactAmélie HERBAUT LECOCQ

Direction de la Recherche Clinique et de l'Innovation

drc@chru-lille.fr003303 20 44 41 45

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026